Kevin Hern
Kevin Hern (R-OK) sold $250K-$500K of $UNH (UnitedHealth Group Incorporated Common Stock) on Dec 23, 2025.
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
5 flagsRep. Kevin Hern sold $250,001 - $500,000 in $UNH on 2025-12-23 — 76 days before HR7861, the 'Care Over Profits Act of 2026,' was introduced, which aims to increase the minimum medical loss ratio for health insurers.
Rep. Kevin Hern sold $250,001 - $500,000 in $UNH on 2025-12-23 — 79 days before HR7895, the 'PBM Kickback Prohibition Act,' was introduced, which directly prohibits compensation for referrals to PBMs.
Rep. Kevin Hern sold $250,001 - $500,000 in $UNH on 2025-12-23 — 79 days before HR7902 was introduced, a bill that would withdraw FDA approval for mifepristone and establish a federal tort for chemical abortion drug harm.
Rep. Kevin Hern sold $250,001 - $500,000 in $UNH on 2025-12-23 — 86 days before SJRES141 was introduced, which seeks to reinstate stricter medical debt collection regulations.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Living Donor Protection Act of 2025
The Living Donor Protection Act of 2025 (S.1552), reported favorably out of committee and on the Senate calendar, prohibits life, disability, and long-term care insurers from discriminating against living organ donors. This removes an underwriting barrier, expands the insured pool, and drives increased transplant volume. Major managed care and insurance stocks have rallied 9-39% in the last 30 days, with this legislation providing a structural tailwind for revenue growth across the sector.
To amend title XXVII of the Public Health Service Act and the Patient Protection and Affordable Care Act to provide for certain reforms with respect to medical loss ratios and reducing fraudulent enrollment in qualified health plans.
HR7861 (Care Over Profits Act) proposes raising the minimum MLR from 80% to 85% for individual/small group health plans. The bill is early-stage, referred to committee, and faces long odds, with only one cosponsor and no companion in the Senate. Despite the bearish direct impact on insurer margins, major health insurer stocks have rallied 7-40% over the past 30 days, indicating the market is not pricing in legislative risk.
To amend title XVIII of the Social Security Act to establish a full risk ACO program.
HR8129, a bill to create a permanent full risk ACO program in traditional Medicare, is at early legislative stage with low momentum (1 cosponsor, 2 committees). Despite this, the four largest Medicare Advantage insurers ($UNH, $HUM, $CNC, $CVS) have already rallied sharply over 30 days — $CNC +62.34%, $HUM +38.49%, $UNH +35.85%, $CVS +16.05% — indicating investors are pricing in the structural shift to value-based care regardless of this specific bill's passage timeline.
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
HR8163 (Provider Reimbursement Stability Act) is an early-stage procedural bill that reduces physician fee cut frequency under Medicare budget neutrality rules, directly benefiting Medicare Advantage insurers. $UNH, $CVS, and $HUM have rallied 3-12% in the past week on bipartisan momentum signals, though zero authorized funding means zero direct revenue impact—only regulatory relief.
Dental Care for Veterans Act
The Dental Care for Veterans Act (HR210) expands VA dental eligibility to all enrolled veterans, creating an estimated $5-10B annual procurement opportunity for dental suppliers. The bill has 95 cosponsors and passed committee hearings but no appropriations are authorized. HSIC and XRAY are the strongest structural beneficiaries given their pure-play dental exposure.
Ensuring Medicaid Continuity for Children in Foster Care Act of 2026
HR8095 is a narrow technical fix allowing federal Medicaid payments for children in foster care placed in qualified residential treatment programs. The bill authorizes zero funding and is at an early legislative stage (referred to committee). Recent rallies in Medicaid MCO stocks like CNC (+62.37% 30-day) and MOH (+46.63% 30-day) are driven by broader sector dynamics, not this niche bill.
To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
PBM Kickback Prohibition Act
HR7895 is an early-stage House bill banning referral compensation to PBMs. It has no Senate companion, sits at the start of the legislative process, and has near-zero passage probability in this Congress. Market data shows the three largest PBM-associated stocks (CVS, UNH, CI) have rallied significantly over the past 30 days — this bill is not a driver of those moves. The bill's impact, if enacted, would be immaterial to all three companies' financials.
To amend title XXVII of the Public Health Service Act to establish civil liability for health insurance issuers with high levels of claims denials.
HR8442 (Patient Refunds for Bad Denials Act) is an early-stage bill with one sponsor and one cosponsor, referred to committee on April 22, 2026. It proposes civil penalties for health insurers with claims denial rates at or above 25%, but faces a long legislative path. Major health insurers ($HUM, $CI, $CVS) have rallied 9-38% over 30 days, and this bill presents no immediate stock-moving catalyst given its procedural stage.
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
S.J. Res. 141 would reinstate stricter medical debt collection rules by disapproving the CFPB's 2025 withdrawal of its 2024 Regulation F rule. For hospital operators like EHC, UHS, and HCA, this increases bad debt expense and compliance costs. The resolution is on the Senate calendar but has not passed—the market impact is currently anticipatory, not realized. EHC has already declined 5.4% in the past two weeks on negative sentiment.
Other Filings by Kevin Hern
Free — no credit card
Get the next Hern trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.